



AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@amdl.com
(Tel :) 206.310.5323

FOR IMMEDIATE RELEASE

**AMDL CEO FEATURED IN CEOCFO MAGAZINE; DETAILS PROGRESS ON
DR-70 INTERNATIONAL COMMERCIALIZATION STRATEGY &
CONFIDENCE IN FY2009 FINANCIAL FORECAST**

(TUSTIN, CA) June 17, 2009/PRNewswire – [AMDL Inc.](#) (NYSE Alternext US: [ADL](#) - [News](#)), a US-based pharmaceutical company with major operations in China, announced today its Chairman and CEO Mr. Douglas MacLellan has been featured in CEOCFO Magazine – a daily online investment news publication that delivers market news and analysis to investors through exclusive interviews with venture capital and publicly-traded companies listed on US and International stock exchanges.

In his interview Mr. MacLellan comments on AMDL's continued focus to become a leading pharmaceutical company with three distinct and growing divisions that include *In Vitro* Diagnostics (IVD), High End Skin Care Products, and China-based Pharmaceuticals; and target goals of achieving profitability across AMDL's US and China-based operations by year end.

Mr. MacLellan also provided updates on AMDL's worldwide commercialization strategy for the Company's DR-70 (FDP) IVD cancer test saying, "We are leveraging last year's US FDA approval for DR-70 with the launch of an international commercialization and have already realized sales revenues in this division. I believe in vitro diagnostics will be a substantial segment for the AMDL -- one that absolutely has the potential to generate equivalent or better returns as compared to our China-based pharmaceutical division."

Since 2006 AMDL has achieved more than 100% in year-over-year gross revenue growth and remains on track with its FY2009 business milestones and financial guidance projections. The Company is featured as the "#1 Small-Cap Stock Pick for 2009" by Flaherty Financial News (www.flahertyfinancialnews.com), a New York-based investment newsletter, and was named one of the Top 5 fastest growing publicly-traded companies in Orange County by international consulting group Deloitte.

The CEOCFO interview of Mr. Maclellan has been published and is available upon request by emailing AMDL's Investor Relations at kszarkowitz@amdl.com or by visiting the CEOCFO website located at ceocfomagazine.com. (User subscription is required.) For additional information on AMDL, its portfolio of products and 2009 business strategy visit the Company's website at www.amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

###